It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Basal cell carcinoma and squamous cell carcinoma are the most common skin cancers, and have genetic overlap with melanoma, pigmentation traits, autoimmune diseases, and blood biochemistry biomarkers. In this multi-trait genetic analysis of over 300,000 participants from Europe, Australia and the United States, we reveal 78 risk loci for basal cell carcinoma (19 previously unknown and replicated) and 69 for squamous cell carcinoma (15 previously unknown and replicated). The previously unknown risk loci are implicated in cancer development and progression (e.g. CDKL1), pigmentation (e.g. TPCN2), cardiometabolic (e.g. FADS2), and immune-regulatory pathways for innate immunity (e.g. IFIH1), and HIV-1 viral load modulation (e.g. CCR5). We also report an optimised polygenic risk score for effective risk stratification for keratinocyte cancer in the Canadian Longitudinal Study of Aging (794 cases and 18139 controls), which could facilitate skin cancer surveillance e.g. in high risk subpopulations such as transplantees.
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common skin cancers and have genetic overlap. Here, the authors use a multi-trait genetic and phenotypic analysis to reveal susceptibility loci for BCC and SCC, and report an optimised polygenic risk score for risk stratification.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 QIMR Berghofer Medical Research Institute, Statistical Genetics Lab, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); Queensland University of Technology, School of Biomedical Sciences, Faculty of Health, Brisbane, Australia (GRID:grid.1024.7) (ISNI:0000000089150953); Queensland University of Technology, Center for Genomics and Personalised Health, Brisbane, Australia (GRID:grid.1024.7) (ISNI:0000000089150953)
2 QIMR Berghofer Medical Research Institute, Statistical Genetics Lab, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); Queensland University of Technology, School of Biomedical Sciences, Faculty of Health, Brisbane, Australia (GRID:grid.1024.7) (ISNI:0000000089150953)
3 QIMR Berghofer Medical Research Institute, Statistical Genetics Lab, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395)
4 23andMe, Inc, Sunnyvale, USA (GRID:grid.420283.f) (ISNI:0000 0004 0626 0858)
5 QIMR Berghofer Medical Research Institute, Cancer Control Group, Brisbane, Australia (GRID:grid.1049.c) (ISNI:0000 0001 2294 1395); University of Queensland, Faculty of Medicine, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
6 University of Queensland, Faculty of Medicine, Brisbane, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)